Wei Zou

Genentech, Inc - South San Francisco / United States

Natural Sciences / Mathematical Sciences

AD Scientific Index ID: 4380781

-

Registration, Add Profile,
Premium Membership

Print Your Certificate

Wei Zou's MOST POPULAR ARTICLES

1-) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialL Fehrenbacher, A Spira, M Ballinger, M Kowanetz, J Vansteenkiste, ...The Lancet 387 (10030), 1837-1846, 201624282016

2-) Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLCRS Herbst, G Giaccone, F de Marinis, N Reinmuth, A Vergnenegre, ...New England Journal of Medicine 383 (14), 1328-1339, 202010492020

3-) Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDR Gandara, SM Paul, M Kowanetz, E Schleifman, W Zou, Y Li, ...Nature medicine 24 (9), 1441-1448, 201810352018

4-) Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia studyDF McDermott, JA Sosman, M Sznol, C Massard, MS Gordon, O Hamid, ...Journal of Clinical Oncology 34 (8), 833-842, 20166002016

5-) IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLCMA Socinski, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ...Journal of Thoracic Oncology 16 (11), 1909-1924, 20213792021

ARTICLES

Add your articles